FDA approves first in class drug for HIV with resistance

The medication lenacapavir for adults living with multi drug resistant HIV infection is approved by FDA. After the initial doses are completed orally and subcut the drug is administered via injection every 6 months.


This offers patients a long awaited twice yearly option who have complex prior treatment histories.


Lenacapavir is a capsid inhibitor that blocks the HIV virus protein shell and interferes with steps in the viral evolution .


This is a drug that would help patients with HIV who have run out of treatment options.